Bio Pharma Dive

OCTOBER 18, 2022

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment

In-Vivo 283

In-Vivo Genetics 283

Bio Pharma Dive

JANUARY 6, 2023

The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio

In-Vivo 252

In-Vivo Gene Editing Gene 252

Pharma Phorum

JUNE 28, 2021

The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the body has yielded impressive results in patients with ATTR amyloidosis, a life-threatening rare disease. . In three more patients treated at 0.1mg/kg levels fell by 52%.

In-Vivo 85

In-Vivo Gene Silencing Gene Editing Genome 85

Scienmag

SEPTEMBER 28, 2020

In-Vivo 81

In-Vivo Research Engineer Medicine 81

BioTech 365

JULY 14, 2022

Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform Triatomic Capital’s Jeff Huber to Join Board of Directors with this Funding … Continue reading → Business Wire

In-Vivo 52

In-Vivo 52

BioTech 365

JULY 5, 2022

In-Vivo 52

In-Vivo 52

BioTech 365

JULY 5, 2022

In-Vivo 52

In-Vivo Medicine Research 52

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T

In-Vivo 203

In-Vivo RNA Medicine Research 203

BioTech 365

NOVEMBER 9, 2020

In-Vivo 52

In-Vivo Development 52

BioTech 365

APRIL 8, 2021

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS

In-Vivo 52

In-Vivo Medicine 52

BioTech 365

DECEMBER 23, 2021

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Orthogonal IL-2 … Continue reading → Business Wire

In-Vivo 52

In-Vivo 52

BioTech 365

DECEMBER 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting – Upregulation of SCN1A … Continue reading → Business Wire

In-Vivo 52

In-Vivo 52

BioTech 365

JUNE 21, 2022

Gene Editing 52

Gene Editing In-Vivo Gene Development 52

BioSpace

SEPTEMBER 29, 2021

EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision

In-Vivo 87

In-Vivo Gene 87

BioSpace

OCTOBER 21, 2021

The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis

In-Vivo 84

In-Vivo Development Drugs 84

BioTech 365

MAY 18, 2022

Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising … Continue reading → Business Wire

Gene Editing 52

Gene Editing In-Vivo Gene 52

BioTech 365

MAY 18, 2022

Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022 Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle … Continue reading → Business Wire

Gene Editing 52

Gene Editing In-Vivo Gene 52

Scienmag

OCTOBER 24, 2021

Therefore, understanding the local invasion mechanism is warranted in developing more effective therapeutic approaches, and identifying markers that predict poor prognosis. SOX9 vitro vivoNiigata, Japan – Oral malignancies represent the seventh most common cancer worldwide. Many diagnosed patients relapse, despite radical resection of the primary oral squamous cell carcinoma (OSCC) lesion.

In-Vitro 58

In-Vitro In-Vivo Development 58

BioTech 365

MAY 2, 2022

In-Vivo 52

In-Vivo Protein 52

BioTech 365

AUGUST 31, 2021

Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit CSO, Cecile … Continue reading → Business Wire

In-Vivo 52

In-Vivo Gene 52

Pharma Phorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology.

In-Vivo 87

In-Vivo Engineer Scientist Life Science 87

BioSpace

JULY 6, 2021

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures

Gene Editing 86

Gene Editing In-Vivo Medicine Gene 86

BioTech 365

AUGUST 25, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 DURHAM, N.C.–(BUSINESS –(BUSINESS WIRE)–Precision BioSciences, Inc. Nasdaq: DTIL), a clinical stage biotechnology company … Continue reading → Business Wire

Gene Editing 40

Gene Editing In-Vivo Gene 40

BioTech 365

JANUARY 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a … Continue reading → Business Wire

In-Vivo 52

In-Vivo Research 52

BioTech 365

MAY 26, 2021

Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Biomedical Microelectromechanical Systems Market … Continue reading → Business Wire

In-Vivo 40

In-Vivo Marketing 40

BioSpace

MARCH 10, 2021

Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome

Genome 80

Genome Genomics In-Vivo Engineer 80

Scienmag

MAY 2, 2022

Due to their ultra-small size (usually less than 10 nm), simple synthesis, low toxicity, well-documented biocompatibility, and outstanding luminescent properties, CDs have attracted wild applications, particularly in bioimaging and biomedical fields.

In-Vivo 72

In-Vivo 72

BioTech 365

SEPTEMBER 15, 2020

In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC meeting on 17 September 2020 AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V.,

Antibody 52

Antibody In-Vivo Drugs 52

BioTech 365

MAY 4, 2022

Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo … Continue reading → Business Wire

In-Vivo 52

In-Vivo Engineer Gene 52

BioTech 365

OCTOBER 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report.Intellia, LogicBio fuel hope for in vivo gene editing with new … Continue reading → #news

Gene Editing 40

Gene Editing In-Vivo Research Gene 40

BioSpace

SEPTEMBER 29, 2020

Draper, in one of the latest lab-on-a-chip advances, has shown that its dynamic, in vitro tumor microenvironment can be used to distinguish tumor responses against two different checkpoint inhibitors in three mouse lines

In-Vitro 81

In-Vitro In-Vivo 81

BioTech 365

MAY 2, 2022

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell … Continue reading → Business Wire

Gene Editing 40

Gene Editing In-Vivo Gene Research 40

BioTech 365

MAY 2, 2022

Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First … Continue reading → GlobeNewswire

Gene Editing 40

Gene Editing In-Vivo Medicine Gene 40

BioTech 365

APRIL 28, 2021

CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of … Continue reading → Business Wire

In-Vivo 52

In-Vivo 52

BioTech 365

APRIL 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading → #news

In-Vivo 40

In-Vivo Research 40

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. Biology developing gap granule insulin labeling model overcome pools researchers secretory translational vivo

Insulin 52

Insulin In-Vivo Regulation Development 52

BioTech 365

APRIL 27, 2021

Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to … Continue reading → GlobeNewswire

In-Vivo 40

In-Vivo Antibody 40

BioTech 365

APRIL 10, 2021

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types … Continue reading → GlobeNewswire

In-Vivo 40

In-Vivo 40

Bio Pharma Dive

NOVEMBER 11, 2020

The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology

In-Vivo 286

In-Vivo Medicine 286

BioSpace

AUGUST 19, 2020

A novel way to control biologic signaling allows cellular function to be modulated via cell phone, according to research presented at the American Chemical Society’s annual meeting Tuesday by researchers at the University of Maryland

In-Vivo 53

In-Vivo Research 53

BioTech 365

MAY 11, 2021

New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting … Continue reading → Business Wire

In-Vivo 40

In-Vivo Genome Genomics Genetics 40

BioTech 365

OCTOBER 19, 2020

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice In vivo breast cancer data show a significant delay in challenge tumor uptake GARDEN CITY, N.Y., 19, 2020 (GLOBE NEWSWIRE) — Beyond Air, Inc. NASDAQ: … Continue reading → GlobeNewswire

In-Vivo 40

In-Vivo Vaccination Vaccine 40

Pharma Times

JANUARY 21, 2021

Antibodies in blood of vaccinated individuals neutralised in vivo version of variant

In-Vivo 103

In-Vivo Antibody Vaccination Vaccine 103